Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 30, 2025

Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2025

View original at globenewswire.com
Ellomay Capital Reports Results for the Three and Nine Months Ended September 30, 2025 TEL-AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- TEL-AVIV, Israel, Dec…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 210 MW of Italian development pipeline reached 'Ready to Build' status with construction scheduled to begin Q4 2026

    80% confidence

  • Regulatory changes and tariff uncertainty limit forecasting beyond current USA plans

    80% confidence

  • Green certificate sales agreements of ~€1/certificate expected to result in significant profitability increase when Netherlands blending obligation starts

    80% confidence

  • Spain needs significant battery storage capacity increase to address grid stability concerns from excess renewable energy

    80% confidence

  • Construction of 160 MW Italian solar project expected to complete by end of 2026

    80% confidence

  • USD exchange rate decline on Dorad deposits creates natural hedge against future USD expenses for gas purchases, O&M, and Dorad 2 construction

    80% confidence

  • Compensation expected from EPC contractor for construction delays in USA projects

    80% confidence

  • Netherlands biogas expansion target capacity of ~24M m³/year gas represents +50% increase from current ~16M m³/year

    80% confidence

  • Dorad 2 project target financial closing date is June 30, 2026

    80% confidence

  • Ellomay Solar license for 28 MWp + 2 hours battery storage expected in coming months

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com